Biosafety, quality control, and simplicity

Designing TME-responsive polymeric nanoparticles should prioritize biocompatibility, scalability, reproducible quality control, and cost-effectiveness. The core challenge in scaling up functional polymeric nanoparticles is translating the complex lab-grade characteristics into consistent, stable, and cost-effective mass production. Therefore, the preparation process should be simplified and optimized as much as possible to improve process stability and manufacturing efficiency. At the same time, a reasonable balance should be achieved between maximizing therapeutic efficacy and minimizing toxicity to ensure both safety and effectiveness of the clinical application. Given the systemic nature of antitumor immunity, combination immunotherapies must balance therapeutic efficacy with potential long-term toxicities or immunogenicity, such as cytokine release syndrome and tissue damage. Thus, combining responsive polymeric nanoparticles with strategies to mitigate the toxic side effects of existing immunotherapies may address current clinical challenges.

Stability and targeting efficiency of nanoparticles

TME-responsive nanodelivery systems are easily cleared from the bloodstream. The tumor targeting efficiency is often limited by individual differences in the EPR effect, resulting in inadequate drug delivery. Consequently, the stability and targeting efficiency of polymeric nanoparticles can be improved by optimizing surface modification, such as employing a dynamic PEGylation strategy that enables the nanoparticles to remain invisible in the bloodstream, then shed PEG in response to pH or enzyme upon reaching the TME to expose the targeting ligand (e.g., RGD peptide). In addition, biomimetic nanocarriers can be fabricated by encapsulating nanoparticles with cell membranes (e.g., red blood cell membranes and macrophage membranes), thereby prolonging circulation time and enhancing tumor chemotaxis. In the future, it is necessary to optimize material design through multidisciplinary approaches that combine computational simulation with high-throughput screening. Computational simulation can narrow the screening scope by predicting molecular interactions and high-throughput screening can enable rapid experimental validation, synergistically accelerating the discovery of optimal polymer materials.

Heterogeneity affects response efficiency

Individual patient differences, disease progression stages, and tumor cell heterogeneity can lead to varying drug delivery efficiencies. The expression and distribution of specific stimuli in the TME are highly heterogeneous and dynamic, resulting in uncontrollable nanoparticle responsiveness and insufficient drug concentrations in some regions. As mentioned above, several multi-responsive polymers have been developed to adapt to different TME conditions, such as polymers co-modified with thioether bonds (ROS-sensitive) and hydrazone bonds (pH-sensitive). Furthermore, intelligent feedback-controlled systems can be designed to incorporate real-time biosensing of the TME to dynamically modulate drug release kinetics. Alternatively, exogenous stimuli, such as photo-irradiation and ultrasound, can be used for local combination therapy to enhance the uniformity of TME regulation.

Preclinical models differ significantly from humans

Animal tumor models cannot fully simulate the complex immunosuppressive environment of the human TME, resulting in discrepancies between experimental results and clinical efficacy. Polymeric nanoparticles must be designed to act in synergy with clinical immunotherapies, such as checkpoint inhibitors and CAR-T therapies, within the specific immune context and without causing additive toxicity or interference. Regulatory authorities have not clarified the approval standards for new nanomedicines and safety evaluations, such as immunogenicity and organ accumulation toxicity, require more comprehensive and rigorous data. Moreover, the core regulatory hurdle for combined nanomedicine and immunotherapy treatments lies in the absence of assessment criteria for composite products, making it challenging to accurately evaluate the unique in vivo behavior, synergistic mechanisms of action, and cumulative toxicity risks. Patient-derived xenografts (PDX) or 3D tumor organoids can be used in preclinical studies to more accurately assess the permeability and immunomodulatory effects of polymeric nanoparticles. Alternatively, humanized mouse models with reconstituted immune systems can be constructed to better simulate human immune responses.